What is HC Wainwright’s Estimate for MLYS Q3 Earnings?

Mineralys Therapeutics, Inc. (NASDAQ:MLYS) – Research analysts at HC Wainwright upped their Q3 2026 EPS estimates for shares of Mineralys Therapeutics in a note issued to investors on Thursday, August 13th. HC Wainwright analyst M. Caufield now forecasts that the company will post earnings of ($0.54) per share for the quarter, up from their previous forecast of ($0.56). HC Wainwright currently has a “Buy” rating on the stock. The consensus estimate for Mineralys Therapeutics’ current full-year earnings is ($4.45) per share. HC Wainwright also issued estimates for Mineralys Therapeutics’ Q4 2026 earnings at ($0.58) EPS, FY2026 earnings at ($4.40) EPS, FY2027 earnings at ($2.12) EPS, FY2028 earnings at ($0.96) EPS, FY2029 earnings at $1.12 EPS and FY2030 earnings at $4.13 EPS.

A number of other brokerages have also issued reports on MLYS. Zacks Research lowered Mineralys Therapeutics from a “hold” rating to a “strong sell” rating in a research report on Thursday, August 13th. Weiss Ratings restated a “sell (d-)” rating on shares of Mineralys Therapeutics in a research note on Friday, July 17th. Jefferies Financial Group restated a “hold” rating on shares of Mineralys Therapeutics in a research report on Monday, June 1st. TD Cowen began coverage on Mineralys Therapeutics in a research report on Monday, April 27th. They issued a “buy” rating on the stock. Finally, Wall Street Zen cut shares of Mineralys Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Saturday, August 15th. Six analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $49.33.

Mineralys Therapeutics Trading Down 1.5%

NASDAQ:MLYS opened at $25.27 on Monday. The firm has a market capitalization of $2.23 billion, a PE ratio of -5.96 and a beta of 0.68. The business’s 50-day moving average is $26.77 and its two-hundred day moving average is $27.26. Mineralys Therapeutics has a 12 month low of $14.53 and a 12 month high of $47.65. The company has a debt-to-equity ratio of 0.18, a current ratio of 34.46 and a quick ratio of 34.46.

Mineralys Therapeutics (NASDAQ:MLYS) last issued its earnings results on Wednesday, August 12th. The company reported ($2.85) earnings per share for the quarter, missing the consensus estimate of ($0.55) by ($2.30).

Insider Activity at Mineralys Therapeutics

In other Mineralys Therapeutics news, insider Eric Warren sold 104,124 shares of the company’s stock in a transaction dated Friday, June 26th. The stock was sold at an average price of $25.90, for a total value of $2,696,811.60. Following the transaction, the insider directly owned 38,400 shares of the company’s stock, valued at $994,560. This represents a 73.06% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider David Malcom Rodman sold 9,890 shares of the stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $23.81, for a total value of $235,480.90. Following the completion of the transaction, the insider owned 57,095 shares in the company, valued at $1,359,431.95. This represents a 14.76% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 216,896 shares of company stock valued at $5,613,000. Company insiders own 18.94% of the company’s stock.

Hedge Funds Weigh In On Mineralys Therapeutics

Several hedge funds have recently bought and sold shares of MLYS. AQR Capital Management LLC acquired a new position in Mineralys Therapeutics during the first quarter valued at approximately $550,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in shares of Mineralys Therapeutics by 4.3% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 17,085 shares of the company’s stock valued at $271,000 after buying an additional 702 shares in the last quarter. Goldman Sachs Group Inc. boosted its holdings in Mineralys Therapeutics by 166.6% during the first quarter. Goldman Sachs Group Inc. now owns 298,395 shares of the company’s stock valued at $4,739,000 after purchasing an additional 186,480 shares in the last quarter. Woodline Partners LP bought a new stake in Mineralys Therapeutics in the first quarter valued at $757,000. Finally, Creative Planning acquired a new stake in shares of Mineralys Therapeutics during the 2nd quarter worth about $336,000. 84.46% of the stock is owned by institutional investors and hedge funds.

About Mineralys Therapeutics

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc and changed its name to Mineralys Therapeutics, Inc in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.